Cervical cancer primary prevention: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) No edit summary |
Nima Nasiri (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut. | Most effective and cost efficient [[primary prevention]] available for cervical cancer is [[vaccination]] against high risk strains of [[human papilloma virus]], which are [[HPV]] 16 and 18 and is given to adoloscent and young women ideally before the sexual debut. | ||
==Primary Prevention== | ==Primary Prevention== | ||
:Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation. <ref name="MarkowitzUnger2009">{{cite journal|last1=Markowitz|first1=L. E.|last2=Unger|first2=E. R.|last3=Saraiya|first3=M.|title=Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges|journal=JNCI Journal of the National Cancer Institute|volume=101|issue=7|year=2009|pages=439–440|issn=0027-8874|doi=10.1093/jnci/djp044}}</ref> | :[[Primary prevention]] method for cervical cancer is vaccination against [[HPV]] types 16 and 18, there are two type of [[FDA]] approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to [[CDC]] recommendation. <ref name="MarkowitzUnger2009">{{cite journal|last1=Markowitz|first1=L. E.|last2=Unger|first2=E. R.|last3=Saraiya|first3=M.|title=Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges|journal=JNCI Journal of the National Cancer Institute|volume=101|issue=7|year=2009|pages=439–440|issn=0027-8874|doi=10.1093/jnci/djp044}}</ref> | ||
:HPV vaccine also is recommended for following target poulation: | :* [[HPV]] vaccine also is recommended for following target poulation: | ||
:* Young homosexual or bisexual men who have sex with men through age 26 | |||
:* HIV infected young adult who have weakened immune system through age 26 | :** Young homosexual or bisexual men who have sex with men through age 26 | ||
:* Young adults who are transgender through age 26 | :** [[HIV]] infected young adult who have weakened immune system through age 26 | ||
:** Young adults who are transgender through age 26 | |||
: | : | ||
:The trade name of the available FDA approved vaccines include: <ref name="pmid19895230">{{cite journal |vauthors=Grce M |title=Primary and secondary prevention of cervical cancer |journal=Expert Rev. Mol. Diagn. |volume=9 |issue=8 |pages=851–7 |date=November 2009 |pmid=19895230 |doi=10.1586/erm.09.64 |url=}}</ref> | :* The trade name of the available [[FDA]] approved vaccines include: <ref name="pmid19895230">{{cite journal |vauthors=Grce M |title=Primary and secondary prevention of cervical cancer |journal=Expert Rev. Mol. Diagn. |volume=9 |issue=8 |pages=851–7 |date=November 2009 |pmid=19895230 |doi=10.1586/erm.09.64 |url=}}</ref> | ||
:* Gardasil, quadrivalent vaccine, composed of HPV 6, 11, 16 and 18. | |||
:* Cervarix, bivalent vaccine, composed of HPV 16 and 18. | :** [[Gardasil]], quadrivalent [[vaccine]], composed of [[HPV]] 6, 11, 16 and 18. | ||
:** [[Cervarix]], bivalent [[vaccine]], composed of [[HPV]] 16 and 18. | |||
==References== | ==References== | ||
Revision as of 17:23, 21 February 2019
|
Cervical cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cervical cancer primary prevention On the Web |
|
American Roentgen Ray Society Images of Cervical cancer primary prevention |
|
Risk calculators and risk factors for Cervical cancer primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
Overview
Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.
Primary Prevention
- Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation. [1]
- HPV vaccine also is recommended for following target poulation:
- Young homosexual or bisexual men who have sex with men through age 26
- HIV infected young adult who have weakened immune system through age 26
- Young adults who are transgender through age 26
References
- ↑ Markowitz, L. E.; Unger, E. R.; Saraiya, M. (2009). "Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges". JNCI Journal of the National Cancer Institute. 101 (7): 439–440. doi:10.1093/jnci/djp044. ISSN 0027-8874.
- ↑ Grce M (November 2009). "Primary and secondary prevention of cervical cancer". Expert Rev. Mol. Diagn. 9 (8): 851–7. doi:10.1586/erm.09.64. PMID 19895230.